Medpace surged over 45% in after-hours trade after Q2 revenue and EPS beat estimates. Net new business rose 12.6% YoY, with strong FY25 guidance pushing retail sentiment to 'extremely bullish'. Traders celebrated outsized options gains. If gains hold, the stock could post its best-ever day, rebounding from a 7% YTD decline amid a broader healthcare revival.